Why Integra LifeSciences (IART) stock is falling today
Integra LifeSciences (IART) shares fell 7.3% after reporting Q3 revenue of $411.2M, meeting expectations, and adjusted EPS of $0.59, beating estimates. The company cited plant flooding and operational disruptions, projecting Q4 revenue of $413M-$433M, below analyst estimates of $433.2M. Rising borrowing costs also weighed on investor sentiment.
How this was made
The 30-second read
Why it matters
The earnings beat on a per‑share basis was offset by a revenue miss and operational risk, leading to a sharp price decline.
Market read
The earnings release and guidance miss constitute a primary market‑moving event for IART, driving immediate downside risk.
What to watch
Potential cost‑saving measures from the flood cleanup and any insurance recoveries are not reflected in the current guidance.
Background
Integra LifeSciences disclosed Q3 revenue of $411.2 M and adjusted EPS of $0.59, but highlighted a $7 M hit from flood damage and a Q4 revenue range below analyst expectations.
Ticker impact
Shares fell 7.3% after Integra LifeSciences reported Q3 results and gave Q4 revenue guidance below estimates, citing flood‑related disruptions.
downward pressure as investors price in weaker revenue outlook and higher borrowing costs
Guidance below consensus and operational risk from flood damage directly triggered the 7% intraday drop.
Market effects
Medical device sector may see heightened scrutiny on supply‑chain resilience after flood disruption.
U.S. healthcare stocks could face modest pullback as investors reassess risk exposure.
Limited to U.S. listed medical‑device peers; no broader macro effect.
Counterpoint
The stock may be oversold; a bounce could occur if the flood impact is contained and guidance is revised upward.
Key entities
- companyIntegra LifeSciences
Medical‑device manufacturer reporting Q3 results and Q4 guidance.
